VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 1, 2018

Primary Completion Date

June 4, 2026

Study Completion Date

November 30, 2027

Conditions

Squamous Cell Carcinoma of the Head and Neck

Interventions

BIOLOGICAL

VX15/2503

Given IV

BIOLOGICAL

Ipilimumab

Given IV

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (1)

RECRUITING

Emory University Hospital Midtown, Atlanta

All Listed Sponsors

collaborator

Vaccinex Inc.

INDUSTRY

lead

Emory University

OTHER